Last updated: 2026-10-19 13:34:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Janux Therapeutics, Inc. (JANX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16.67, with a market capitalization of $1.01B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.12 to $35.34. This page covers its latest market performance, valuation, price trends and company information.
$1.01B | |
$16.51 | |
$71.71 | |
$5.65 | |
$16.51 | |
4.67K | |
844.45K | |
-- | |
$35.34 | |
$12.12 | |
-- | |
-- |
Janux Therapeutics, Inc. (JANX) is currently trading at $16.67 as of 2026-10-19 13:33:00, up 0.99% ($0.16) from the previous close of $16.51
During today's regular trading session, JANX has traded between $5.65 and $71.71, with a trading volume of 4.67K shares. The current price is near the lower end of today's range.
Over the past seven days, Janux Therapeutics, Inc. (JANX) moved from $18.50 to $16.67, representing a decline of 9.87% ($1.83).
The stock traded between $16.19 and $19.18 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 885.60 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 19.6%
JANX is currently trading at $16.67, placing it 19.6% of the way from its 52-week low of $12.12 to its 52-week high of $35.34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 113 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Janux Therapeutics, Inc. (JANX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.